Study #2024-0109
A multicenter, open-label, phase 1a/1b study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as monotherapy and in combination with Tislelizumab in patients with advanced or metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
BGB-B3227, Tislelizumab, Chemotherapy
Description
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended dose(s) for expansion (RDFE\[s\]) of BGB-B3227 administered alone and in combination with tislelizumab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
Study phase:
Phase I
Physician name:
Ecaterina Ileana Dumbrava
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-946-3759
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.